Northern Trust Corp Metacrine, Inc. Transaction History

Northern Trust Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $0.55 $4,095 - $5,238	9,524 Added 57.24%	26,163 $13,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $11,504 - $16,926	4,408 Added 36.04%	16,639 $57,000
Q2 2021 Aug 13, 2021	SELL	$3.37 - $5.73 $200,774 - $341,376	-59,577 Reduced 82.97%	12,231 $46,000
Q1 2021 May 12, 2021	SELL	$6.2 - $11.0 $36,208 - $64,240	-5,840 Reduced 7.52%	71,808 $445,000
Q4 2020 Feb 11, 2021	BUY	$7.75 - $11.42 $601,772 - $886,740	77,648 New	77,648 $611,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.